<DOC>
	<DOCNO>NCT00171808</DOCNO>
	<brief_summary>In Western industrialized country , endometrial cancer common malignancy female reproductive tract . The general therapy option surgery , radiotherapy , chemotherapy endocrine therapy . This trial investigate efficacy safety letrozole treatment advance recurrent hormone receptor-positive endometrial cancer .</brief_summary>
	<brief_title>Letrozole Treatment Advanced Recurrent Hormone Receptor Positive Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Signed informed consent Age &gt; 18 year Presence histologically proven adenocarcinoma adenosquamous carcinoma endometrium Presence advance recurrent endometrial cancer , FIGO stage IIV , incurable surgery and/or radiation therapy Documented ER and/or PgR positive endometrial cancer . Hormone receptor positivity define accord routine practice participate laboratory . Patient must postmenopausal defined Age ≥55 year . Age &lt; 55 spontaneous menses least 1 year . Age &lt; 55 spontaneous menses within past 1 year , currently amenorrheic ( e.g. , spontaneous secondary hysterectomy ) , postmenopausal gonadotrophin level ( luteinizing hormone follicle stimulate hormone level &gt; 40 IU/L ) postmenopausal estradiol level ( &lt; 5 ng/dL ) accord definition `` postmenopausal range '' laboratory involve . Bilateral oophorectomy Radiation menopause Presence measurable disease ( clinical/radiological examination accord RECIST criterion : minimum indicator lesion size : 20 mm ( unless spiral CT scan case &gt; 10 mm ) ECOG performance status 0 , 1 2 Adequate bone marrow function ( WBC ≥ 3.5 x 1'000'000'000/L platelet ≥ 100.0 x 1'000'000'000/L ) hemoglobin &gt; 10.0 g/dl Adequate renal function ( creatinine &lt; 120 µmol/L ) hepatic function ( bilirubin &lt; 25 µmol/L , AST ( SGOT &lt; 60 U/L ) Minimum life expectancy least 6 month Patients accessible treatment followup Presence nonmeasurable disease Other concomitant anticancer treatment ( except external radiation treatment [ XRT ] symptomatic metastatic lesion assessable untreated lesion present ) Prior treatment aromatase inhibitor antiestrogens ( one previous progestational hormone therapy regimen recurrent disease permit ) Clear cell papillary serous histology , uterine sarcoma , mixed Mullerian tumor ( MMT ) and/or adenosarcomas Other concurrent malignant disease exception conebiopsied situ carcinoma cervix uterus , adequately treat basal squamous cell carcinoma skin , curable cancer e.g . Hodgkin ` disease nonHodgkin lymphoma ( NHL ) , provide 5 year elapsed completion therapy , recurrence Known central nervous system ( CNS ) metastases , bilateral diffuse lymphangiosis carcinoma lung ( &gt; 50 % lung involvement , dyspnea rest require supplemental oxygen therapy ) , evidence metastasis estimate third liver define sonogram and/or CT scan Uncontrolled endocrine disorder diabetes mellitus , confirm hypo hyperthyroidism , Cushing ` Syndrome , Addison ` disease ( treat untreated ) Unstable angina uncontrolled cardiac disease Treatment investigational drug ( drug market indication ) within past 30 day and/or concomitant use investigational drug A history noncompliance medical regimens patient , opinion investigator , unlikely cooperate fully study Inability swallow pill Additional protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Endometrial Cancer</keyword>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>Advanced recurrent</keyword>
	<keyword>hormone receptor positive</keyword>
</DOC>